ArticleBMC women's health2026
Mesh-sacropexy in women with apical pelvic organ prolapse - results of a single-centre prospective cohort study.
Article in BMC women's health, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Tissue Reaction to Monofilament Grafts of Different Weights Used for Abdominal Wall Reinforcement.Biomedicines · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPelvic organ prolapse (POP) affects nearly half of women, highly influencing quality of life. When conservative treatment fails, surgical repair is indicated, with sacropexy representing the current gold standard for apical POP (aPOP) repair.
methodsProspective single-centre cohort study including patients (pts) with aPOP and indication for surgery using polyvinylidene fluoride (PVDF) mesh (DynaMesh®) for sacrocervicopexy, sacrocolpopexy, or sacrohysteropexy at the University Hospital Bonn. Clinical data, peri- and postoperative outcomes, and follow-ups at 8 weeks (FU2), 6 months (FU3), and 12 months (FU4) postoperatively were analysed. The primary endpoint was the recurrence at FU4, defined as aPOP-Q ≥ grade II. Secondary endpoints included quality of life using the German Pelvic Floor Questionnaire (GPFQ), International Consultation on Incontinence Questionnaire – Urinary Incontinence Short Form (ICIQ-UI-SF), and a study-specific questionnaire.
resultsA total of 90 women (median age 60 years [range 34–83], median body mass index 24.5 kg/m² [range 19.5–40.3]) underwent POP surgery between 2022 and 2024. Most procedures were robotic-assisted sacrocervicopexies (77.8%). Perioperative complications occurred in 4.4% (intraoperative) and 6.7% (postoperative) of cases. Median hospital stay was 5 days (range 3–9). Until FU4, no apical recurrences were observed; cumulatively, de-novo mesh erosion occurred in 4.4% of pts, with 2.2% requiring surgical revision. De-novo urinary incontinence was rare (5.5%). Subjective outcomes included scores of GPFQ and ICIQ-UI-SF, which improved significantly at all follow-up visits compared to preoperatively. 93% of pts were satisfied with the operation, 94% would choose it again, and 95% of pts would recommend this operation to a friend.
conclusionsMesh-assisted sacropexy was associated with high apical success rates and favourable patient-reported outcomes at 12 months. Complication and reoperation rates were low within the observed follow-up period. However, longer-term data are required to fully evaluate durability and safety.
trial registrationRegistration number: DRKS00038856. Registration date: 08th January 2026, registered retrospectively
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.